Format

Send to

Choose Destination
Crit Care. 2018 Feb 26;22(1):51. doi: 10.1186/s13054-018-1969-1.

Intraoperative milrinone versus dobutamine in cardiac surgery patients: a retrospective cohort study on mortality.

Author information

1
Department of Anesthesia and Intensive Care, Aarhus University Hospital, Palle Juul-Jensens Boulevard, 8200, Aarhus N, Denmark. dorthe.viemose.nielsen@skejby.rm.dk.
2
Department of Health, Science and Technology, Aalborg University, Frederiks Bajersvej, 9220, Aalborg, Denmark.
3
Unit of Epidemiology and Biostatistics, Aalborg University Hospital, Forskningens Hus, Sdr. Skovvej 15, 9000, Aalborg, Denmark.
4
Department of Public Health, Section of Biostatistics, University of Copenhagen, Oester Farimagsgade 5, 1014, Copenhagen, Denmark.
5
Department of Anesthesia and Intensive Care, Aarhus University Hospital, Palle Juul-Jensens Boulevard, 8200, Aarhus N, Denmark.

Abstract

BACKGROUND:

Several choices of inotropic therapy are available and used in relation to cardiac surgery. Comparisons are necessary to select optimal therapy. In Denmark, dobutamine and milrinone are the two inotropic agents most commonly used to treat post-bypass low cardiac output syndrome. This study compares all-cause mortality with these drugs.

METHODS:

In a retrospective observational study we investigated 10,700 consecutive patients undergoing cardiac surgery from 1 April 2006 to 31 December 2013 at Aarhus and Aalborg University Hospitals in the Central and Northern Denmark Region. Prospectively entered data in the Western Danish Heart Registry on intraoperative use of inotropes were used to identify 952 patients treated with milrinone, 418 patients treated with dobutamine, and 82 patients receiving a combination of the two inotropes. All-cause mortality among patients receiving dobutamine was compared to all-cause mortality among milrinone receivers. Multiple logistic regression analyses including preoperative and intraoperative variables along with g-formula analyses were used to model 30-day and 1-year mortality risks. Reported were standardized mortality risk differences between the treatment groups.

RESULTS:

Among patients receiving intraoperative dobutamine, 18 (4.3%) died within 30 days and 49 (11.7%) within 1 year. Corresponding 30-day and 1-year mortality for milrinone receivers were 81 (8.5%) and 170 (17.9%). Risk of death within 30 days and 1 year was increased for intraoperative milrinone compared to dobutamine with a standardized risk difference of 4.06% (confidence interval (CI) 1.23; 6.89, p = 0.005) and 4.77% (CI 0.39; 9.15, p = 0.033), respectively. Sensitivity analyses including adjustment for milrinone preference, hemodynamic instability prior to cardiopulmonary bypass, and separate analyses on hospital level all confirmed a sign toward increased mortality among milrinone receivers.

CONCLUSIONS:

Intraoperative use of milrinone in cardiac surgery may be associated with an increase in all-cause mortality compared to use of dobutamine.

KEYWORDS:

Cardiac surgery; Dobutamine; Intraoperative; Milrinone; Mortality; Retrospective cohort study; Standardized mortality risk; g-formula

PMID:
29482650
PMCID:
PMC5828330
DOI:
10.1186/s13054-018-1969-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center